The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases

Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased product...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-03, Vol.23 (7), p.3439
Main Authors: Steenbeke, Mieke, Speeckaert, Reinhart, Desmedt, Stéphanie, Glorieux, Griet, Delanghe, Joris R, Speeckaert, Marijn M
Format: Article
Language:English
Subjects:
advanced glycation end products (AGEs)
Advanced glycosylation end products
Age
Binding sites
Biomarkers
Body mass index
Cardiovascular Diseases
Chromatography
Chronic illnesses
chronic kidney disease (CKD)
Cytokines
Diabetes
Glycation End Products, Advanced
Glycosylation
Humans
Inflammation
Kidney diseases
Kinases
Ligands
NF-κB protein
Oxidative stress
Proteins
Receptor for Advanced Glycation End Products
Renal Insufficiency, Chronic
Review
Risk analysis
Risk factors
Skin
soluble receptor for AGEs (sRAGE)
Toxicity
Tumor necrosis factor-TNF
Uremia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23073439